Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide, Elotuzumab, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT05981209Phase 1Active, not recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mezigdomide in multiple myeloma (MM). Primary endpoints: Recommended Phase 2 Dose at 28 days and Adverse Events at 2 years. Started Dec 2023; status: active, not recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05981209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05981209.